Long-Term Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks in Patients with Plaque Psoriasis: Pooled 128-Week Data from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)

Main Article Content

K Gordon
R.B. Warren
A.B. Gottlieb
A Blauvelt
D Thaci
C Leonardi
Y Poulin
M Boehnlein
S Kavanagh
C Arendt
K Reich

Keywords

psoriasis, certolizumab

Abstract

Abstract not available.

References

1. Parisi R. et al. J Invest Dermatol. 2013;133:377–85.

2. Certolizumab Pegol Prescribing Information. Available at http://www.accessdata.fda.gov.

3. Certolizumab Pegol Summary of Product Characteristics. Available at http://www.ema.europa.eu/ema.

4. Gottlieb AB. et al. JAAD. 2018;79:302–14.e6.

5. Choi J. et al. JAAD. 2003;49:S57–61.

6. Tada Y. et al. J Dermatol. 2019;46:466−477.